Moderna Inc (MRNA)

[axelvento]

Merck and Moderna are testing the combination in other cancers where Keytruda is already used. Earlier this week, the companies said they began a late-stage trial of the combination in lung cancer patients
Stéphane Bancel said the companies want to talk to regulators about getting the skin cancer vaccine approved on a faster timeline. The cancer vaccine could launch as early as 2025, Bancel said in an interview with CNBC.

“If you look at the next 24 months, it’s going to be very dense news flow, very dense product launches,” he said.

He added that the manufacturing for the personalized vaccine, which is produced based on each recipient's DNA, has been reduced to just 30 days from diagnosis to treatment